A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results

Anjali S. Advani; Brenda Cooper; Valeria Visconte; Paul Elson; E. Ricky Chan; Jennifer S. Carew; Sudipto Mukherjee; Aaron T. Gerds; Hetty E. Carraway; Aziz Nazha

doi:10.1182/blood.v130.suppl_1.150.150

A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results

Identifier:nobleid.org/w1/20260515/40DF9D02

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/40DF9D02.svg?ark=w1%2F20260515%2F40DF9D02)](https://nobleid.org/work/w1/20260515/40DF9D02)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results

Identifier:nobleid.org/w1/20260515/40DF9D02

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/40DF9D02.svg?ark=w1%2F20260515%2F40DF9D02)](https://nobleid.org/work/w1/20260515/40DF9D02)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work